1-20 of 20
Hartmut Koeppen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer

Robert Piskol, Ling Huw, Ismail Sergin, Christiaan Kljin, Zora Modrusan, Doris Kim, Noelyn Kljavin, Rachel Tam, Rajesh Patel, Jeremy Burton, Elicia Penuel, Xueping Qu, Hartmut Koeppen, Teiko Sumiyoshi, Frederic de Sauvage, Mark R. Lackner, Felipe de Sousa e Melo, Omar Kabbarah
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (14): 4431–4442.
https://doi.org/10.1158/1078-0432.CCR-18-3032
Published: 15 July 2019
View article titled, A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer
Open the PDF for A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer in another window
Includes: Supplementary data
Journal Articles

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma

Yibing Yan, Matthew J. Wongchenko, Caroline Robert, James Larkin, Paolo A. Ascierto, Brigitte Dréno, Michele Maio, Claus Garbe, Paul B. Chapman, Jeffrey A. Sosman, Zhen Shi, Hartmut Koeppen, Jessie J. Hsu, Ilsung Chang, Ivor Caro, Isabelle Rooney, Grant A. McArthur, Antoni Ribas
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (11): 3239–3246.
https://doi.org/10.1158/1078-0432.CCR-18-0720
Published: 01 June 2019
View article titled, Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with <em>BRAF</em><sup>V600</sup>-mutated Metastatic Melanoma
Open the PDF for Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with <em>BRAF</em><sup>V600</sup>-mutated Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

Saoirse O. Dolly, Andrew J. Wagner, Johanna C. Bendell, Hedy L. Kindler, Lee M. Krug, Tanguy Y. Seiwert, Marjorie G. Zauderer, Martijn P. Lolkema, Doris Apt, Ru-Fang Yeh, Jill O. Fredrickson, Jill M. Spoerke, Hartmut Koeppen, Joseph A. Ware, Jennifer O. Lauchle, Howard A. Burris, 3rd, Johann S. de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (12): 2874–2884.
https://doi.org/10.1158/1078-0432.CCR-15-2225
Published: 14 June 2016
View article titled, Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine

Joyce O'Shaughnessy, Hartmut Koeppen, Yuanyuan Xiao, Mark R. Lackner, Devchand Paul, Christopher Stokoe, John Pippen, Jr, Lea Krekow, Frankie Ann Holmes, Svetislava Vukelja, Deborah Lindquist, Scot Sedlacek, Ragene Rivera, Robert Brooks, Kristi McIntyre, Carrie Brownstein, Silke Hoersch, Joanne L. Blum, Stephen Jones
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (19): 4305–4311.
https://doi.org/10.1158/1078-0432.CCR-15-0636
Published: 30 September 2015
View article titled, Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine
Open the PDF for Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine in another window
Includes: Supplementary data
Journal Articles

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

Hartmut Koeppen, Wei Yu, Jiping Zha, Ajay Pandita, Elicia Penuel, Linda Rangell, Rajiv Raja, Sankar Mohan, Rajesh Patel, Rupal Desai, Ling Fu, An Do, Vaishali Parab, Xiaoling Xia, Tom Januario, Sharianne G. Louie, Ellen Filvaroff, David S. Shames, Ignacio Wistuba, Marina Lipkind, Jenny Huang, Mirella Lazarov, Vanitha Ramakrishnan, Lukas Amler, See-Chun Phan, Premal Patel, Amy Peterson, Robert L. Yauch
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (17): 4488–4498.
https://doi.org/10.1158/1078-0432.CCR-13-1836
Published: 01 September 2014
View article titled, Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit
Open the PDF for Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit in another window
Includes: Supplementary data
Journal Articles

High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing

Richard Bourgon, Shan Lu, Yibing Yan, Mark R. Lackner, Weiru Wang, Victor Weigman, David Wang, Yinghui Guan, Lisa Ryner, Hartmut Koeppen, Rajesh Patel, Garret M. Hampton, Lukas C. Amler, Yulei Wang
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (8): 2080–2091.
https://doi.org/10.1158/1078-0432.CCR-13-3114
Published: 15 April 2014
View article titled, High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing
Open the PDF for High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing in another window
Includes: Supplementary data
Journal Articles

Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors

David S. Shames, Kristi Elkins, Kimberly Walter, Thomas Holcomb, Pan Du, Dane Mohl, Yang Xiao, Thinh Pham, Peter M. Haverty, Bianca Liederer, Xiaorong Liang, Robert L. Yauch, Thomas O'Brien, Richard Bourgon, Hartmut Koeppen, Lisa D. Belmont
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (24): 6912–6923.
https://doi.org/10.1158/1078-0432.CCR-13-1186
Published: 16 December 2013
View article titled, Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors
Open the PDF for Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors in another window
Includes: Supplementary data
Journal Articles

Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

Matthew J. Brauer, Guanglei Zhuang, Maike Schmidt, Jenny Yao, Xiumin Wu, Joshua S. Kaminker, Stefanie S. Jurinka, Ganesh Kolumam, Alicia S. Chung, Adrian Jubb, Zora Modrusan, Tomoko Ozawa, C. David James, Heidi Phillips, Benjamin Haley, Rachel N.W. Tam, Anne C. Clermont, Jason H. Cheng, Sherry X. Yang, Sandra M. Swain, Daniel Chen, Stefan J. Scherer, Hartmut Koeppen, Ru-Fang Yeh, Peng Yue, Jean-Philippe Stephan, Priti Hegde, Napoleone Ferrara, Mallika Singh, Carlos Bais
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2013) 19 (13): 3681–3692.
https://doi.org/10.1158/1078-0432.CCR-12-3635
Published: 30 June 2013
View article titled, Identification and Analysis of <em>In Vivo</em> VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
Open the PDF for Identification and Analysis of <em>In Vivo</em> VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies in another window
Includes: Supplementary data
Journal Articles

Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models

Jie Lin, Deepak Sampath, Michelle A. Nannini, Brian B. Lee, Michael Degtyarev, Jason Oeh, Heidi Savage, Zhengyu Guan, Rebecca Hong, Robert Kassees, Leslie B. Lee, Tyler Risom, Stefan Gross, Bianca M. Liederer, Hartmut Koeppen, Nicholas J. Skelton, Jeffrey J. Wallin, Marcia Belvin, Elizabeth Punnoose, Lori S. Friedman, Kui Lin
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (7): 1760–1772.
https://doi.org/10.1158/1078-0432.CCR-12-3072
Published: 02 April 2013
View article titled, Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
Open the PDF for Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models in another window
Includes: Supplementary data
Journal Articles

Abstract PR6: Widespread potential for growth factor-driven resistance to anti-cancer kinase inhibitors

Timothy R. Wilson, Jane Fridlyand, Antoni Ribas, Jiang Li, Hartmut Koeppen, Mark Merchant, Richard Neve, Jeff Settleman, Yibing Yan, Elicia Penuel, Luciana Burton, Emily Chan, Jing Peng, Eva Lin, Yulei Wang, Jeff Sosman
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): PR6.
https://doi.org/10.1158/1078-0432.MECHRES-PR6
Published: 04 March 2013
View article titled, Abstract PR6: Widespread potential for growth factor-driven resistance to anti-cancer kinase inhibitors
Open the PDF for Abstract PR6: Widespread potential for growth factor-driven resistance to anti-cancer kinase inhibitors in another window
Journal Articles

Abstract B14: Inherent resistance to BRAF inhibitors in BRAFV600E colorectal tumors is driven by ligand-dependent activation of the EGFR pathway

Ivana Yen, Bonnie Liu, Hartmut Koeppen, Georgia Hatzivassiliou, Shiva Malek, Kyung Song, Patricia Pacheco, Leanne Berry Ross, Stephen Gould, Stephen Schmidt, Joachim Rudolph, Lori Friedman, Marcia Belvin
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): B14.
https://doi.org/10.1158/1078-0432.MECHRES-B14
Published: 04 March 2013
View article titled, Abstract B14: Inherent resistance to BRAF inhibitors in BRAFV600E colorectal tumors is driven by ligand-dependent activation of the EGFR pathway
Open the PDF for Abstract B14: Inherent resistance to BRAF inhibitors in BRAFV600E colorectal tumors is driven by ligand-dependent activation of the EGFR pathway in another window
Journal Articles

Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models

Jill M. Spoerke, Carol O'Brien, Ling Huw, Hartmut Koeppen, Jane Fridlyand, Rainer K. Brachmann, Peter M. Haverty, Ajay Pandita, Sankar Mohan, Deepak Sampath, Lori S. Friedman, Leanne Ross, Garret M. Hampton, Lukas C. Amler, David S. Shames, Mark R. Lackner
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (24): 6771–6783.
https://doi.org/10.1158/1078-0432.CCR-12-2347
Published: 16 December 2012
View article titled, Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models
Open the PDF for Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models in another window
Includes: Supplementary data
Journal Articles

Targeting the PI3K Pathway in the Brain—Efficacy of a PI3K Inhibitor Optimized to Cross the Blood–Brain Barrier

Laurent Salphati, Timothy P. Heffron, Bruno Alicke, Merry Nishimura, Kai Barck, Richard A. Carano, Jonathan Cheong, Kyle A. Edgar, Joan Greve, Samir Kharbanda, Hartmut Koeppen, Shari Lau, Leslie B. Lee, Jodie Pang, Emile G. Plise, Jenny L. Pokorny, Hani Bou Reslan, Jann N. Sarkaria, Jeffrey J. Wallin, Xiaolin Zhang, Stephen E. Gould, Alan G. Olivero, Heidi S. Phillips
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (22): 6239–6248.
https://doi.org/10.1158/1078-0432.CCR-12-0720
Published: 14 November 2012
View article titled, Targeting the PI3K Pathway in the Brain—Efficacy of a PI3K Inhibitor Optimized to Cross the Blood–Brain Barrier
Open the PDF for Targeting the PI3K Pathway in the Brain—Efficacy of a PI3K Inhibitor Optimized to Cross the Blood–Brain Barrier in another window
Includes: Supplementary data
Journal Articles

GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo

Jeffrey J. Wallin, Jane Guan, Wei Wei Prior, Leslie B. Lee, Leanne Berry, Lisa D. Belmont, Hartmut Koeppen, Marcia Belvin, Lori S. Friedman, Deepak Sampath
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (14): 3901–3911.
https://doi.org/10.1158/1078-0432.CCR-11-2088
Published: 15 July 2012
View article titled, GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death <em>In Vitro</em> and <em>In Vivo</em>
Open the PDF for GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death <em>In Vitro</em> and <em>In Vivo</em> in another window
Includes: Supplementary data
Journal Articles

Abstract B8: Targeting p21-activated kinases in human lung cancer

Christy C. Ong, Adrian M. Jubb, Peter M. Haverty, Wei Zhou, Adrian L. Harris, Marcia Belvin, Lori S. Friedman, Hartmut Koeppen, Klaus P. Hoeflich
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (3_Supplement): B8.
https://doi.org/10.1158/1078-0432.12AACRIASLC-B8
Published: 01 February 2012
View article titled, Abstract B8: Targeting p21-activated kinases in human lung cancer
Open the PDF for Abstract B8: Targeting p21-activated kinases in human lung cancer in another window
Journal Articles

Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer

Adrian M. Jubb, Kathy D. Miller, Hope S. Rugo, Adrian L. Harris, Dafeng Chen, James D. Reimann, Melody A. Cobleigh, Maike Schmidt, Virginia K. Langmuir, Kenneth J. Hillan, Daniel S. Chen, Hartmut Koeppen
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (2): 372–381.
https://doi.org/10.1158/1078-0432.CCR-10-1791
Published: 16 January 2011
View article titled, Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer
Open the PDF for Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Cooperation of the Agonistic DR5 Antibody Apomab with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival

Hongkui Jin, Renhui Yang, Jed Ross, Sharon Fong, Richard Carano, Klara Totpal, David Lawrence, Zhong Zheng, Hartmut Koeppen, Howard Stern, Ralph Schwall, Avi Ashkenazi
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (23): 7733–7740.
https://doi.org/10.1158/1078-0432.CCR-08-0670
Published: 01 December 2008
View article titled, Cooperation of the Agonistic DR5 Antibody Apomab with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival
Open the PDF for Cooperation of the Agonistic DR5 Antibody Apomab with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival in another window
Journal Articles

Comments on Plasmalemmal Vesicle Associated Protein-1 as a Novel Marker Implicated in Brain Tumor Angiogenesis

Laura A. Sanders (Strickland), Hartmut Koeppen
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (8): 2649.
https://doi.org/10.1158/1078-0432.CCR-05-2624
Published: 25 April 2006
View article titled, Comments on Plasmalemmal Vesicle Associated Protein-1 as a Novel Marker Implicated in Brain Tumor Angiogenesis
Open the PDF for Comments on Plasmalemmal Vesicle Associated Protein-1 as a Novel Marker Implicated in Brain Tumor Angiogenesis in another window
Journal Articles

EphB2 is a Prognostic Factor in Colorectal Cancer

Adrian M. Jubb, Fiona Zhong, Sheila Bheddah, Heike I. Grabsch, Gretchen D. Frantz, Wolfram Mueller, Vidya Kavi, Phil Quirke, Paul Polakis, Hartmut Koeppen
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (14): 5181–5187.
https://doi.org/10.1158/1078-0432.CCR-05-0143
Published: 20 July 2005
View article titled, EphB2 is a Prognostic Factor in Colorectal Cancer
Open the PDF for EphB2 is a Prognostic Factor in Colorectal Cancer in another window
Journal Articles

HER2-Targeted Therapy Reduces Incidence and Progression of Midlife Mammary Tumors in Female Murine Mammary Tumor Virus huHER2-Transgenic Mice

David Finkle, Zhi Ricky Quan, Vida Asghari, Jessica Kloss, Nazli Ghaboosi, Elaine Mai, Wai Lee Wong, Philip Hollingshead, Ralph Schwall, Hartmut Koeppen, Sharon Erickson
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (7): 2499–2511.
https://doi.org/10.1158/1078-0432.CCR-03-0448
Published: 08 April 2004
View article titled, HER2-Targeted Therapy Reduces Incidence and Progression of Midlife Mammary Tumors in Female Murine Mammary Tumor Virus huHER2-Transgenic Mice
Open the PDF for HER2-Targeted Therapy Reduces Incidence and Progression of Midlife Mammary Tumors in Female Murine Mammary Tumor Virus huHER2-Transgenic Mice in another window